Roxithromycin: Review of its antimicrobial activity

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. B, 1998, Pages 1-21

  Bryskier, A ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DAPSONE; DIRITHROMYCIN; ERYTHROMYCIN; ERYTHRONOLIDE A; JOSAMYCIN; LACTONE; MACROLIDE; METRONIDAZOLE; PYRIMETHAMINE; RIFAMPICIN; ROKITAMYCIN; ROXITHROMYCIN; SULFAMETHOXAZOLE;

ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM CULTURE; BORDETELLA; BORRELIA; CAMPYLOBACTER; CELLULAR DISTRIBUTION; CHLAMYDIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; INTRAPERITONEAL DRUG ADMINISTRATION; LEGIONELLA; LISTERIA; MACROPHAGE; MORAXELLA CATARRHALIS; MYCOBACTERIUM; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOPLASMA PNEUMONIAE; NEISSERIA MENINGITIDIS; NEUTROPHIL; NONHUMAN; ORAL DRUG ADMINISTRATION; PARASITOSIS; POSTANTIBIOTIC EFFECT; REVIEW; RICKETTSIA; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031924258     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_2.1     Document Type: Review

References (187)

1. Bryskier, A., Agouridas, C. & Gase, J.-C. (1993). Classification of macrolide antibiotics. In Macrolides, Chemistry, Pharmacology and Clinical Uses (Bryskier, A. J., Butzler, J. P., Neu, H. C. & Tulkens, P. M., Eds), pp. 5-66. Arnette-Blackwell, Paris.
2. Gasc, J.-C., Gouin d'Ambrières, S. G., Lutz, A. & Chantot, J.-F. (1991). New ether oxime derivatives of erythromycin A. A structure-activity relationship study. Journal of Antibiotics 44, 313-30.
3. Nishino, T., Takeda, F. & Tanino, T. (1988). In vitro and in vivo antibacterial activity of RU 28965, a new macrolide antibiotic. Chemotherapy (Tokyo) 36, Suppl. 4, 79-93.
4. Oguri, T. & Hayashi, Y. (1988). In vitro activity of RU 28965 against recent clinical isolates. Chemotherapy (Tokyo) 36, Suppl. 4, 53-64.
5. Siebor, E. & Kazmierczak, A. (1993). Factors influencing the activity of macrolide antibiotics in vitro. In Macrolides, Chemistry, Pharmacology and Clinical Uses (Bryskier, A. J., Butzler, J. P., Neu, H. C. & Tulkens, P. M., Eds), pp. 197-203. Arnette-Blackwell, Paris.
6. Jones, R. N., Barry, A. L. & Thornsberry, C. (1983). In vitro evaluation of three new macrolide antimicrobial agents, RU 28965, RU 29065, RU 29702, and comparisons with other orally administered drugs. Antimicrobial Agents and Chemotherapy 24, 209-15.
7. Chantot, J.-F., Bryskier, A. & Gasc, J.-C. (1986). Antibacterial activity of roxithromycin: a laboratory evaluation. Journal of Antibiotics 39, 660-8.
8. Dette, G. A., Knothe, H. & Koulen, G. (1987). Comparative in vitro, serum binding and binding activity interactions of the macrolides A-56268, RU 28965, erythromycin and josamycin. Drugs under Experimental and Clinical Research 13, 567-76.
9. Yokota, K., Bhatacharya, I., Suzuki, E. & Arai, K. (1988). In vitro antibacterial activity of the semi-synthetic macrolide RU 28965 synergy with serum, complement and lysozyme; synergistic phagocytic effect with leucocytes. Chemotherapy (Tokyo) 36, Suppl. 4, 35-52.
10. Andrews, J. M., Ashby, J. P. & Wise, R. (1987). Factors affecting the in vitro activity of roxithromycin. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 31-7.
11. Felmingham, D., Robbins, M. J., Marais, R., Ridgway, G. L. & Grüneberg, R. N. (1987). The effect of carbon dioxide on the in vitro activity of erythromycin and RU 28965 against anaerobic bacteria. Drugs under Experimental and Clinical Research 13, 195-9.
12. Rosenblatt, J. E. & Schoenknecht, F. (1972). Effect of several components of anaerobic incubation on antibiotic susceptibility test results. Antimicrobial Agents and Chemotherapy 1, 433-40.
13. 2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin and roxithromycin. Antimicrobial Agents and Chemotherapy 38, 211-6.
14. Jones, R. N., Barry, A. L., Fuchs, P. C. & Thornsberry, C. (1986). Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965). Journal of Clinical Microbiology 24, 233-9.
15. Duval, J., Acar, J. F., Cluzel, R., Soussy, C. J., Kitzis, M. C. & Chanal, M. (1988). In vitro activity of roxithromycin against hospital bacteria: regression curve. British Journal of Clinical Practice 42, Suppl. 55, 26-9.
16. Olsson-Liljequist, B. and the Subcommittee on Standardization of Methodology; Swedish Reference Group for Antibiotics. (1991). Susceptibility of bacteria to roxithromycin and definition of interpretative criteria based on a Swedish multicentre study. In Proceedings of the 17th International Congress Chemotherapy, Berlin, 1991. Abstract 771, p.192.
17. National Committee for Clinical Laboratory Standards. (1984). Performance Standard for Antimicrobial Disk Susceptibility Tests. M2-A3. NCCLS, Villanova, PA.
18. National Committee for Clinical Laboratory Standards. (1985). Standard Method for Dilution Antimicrobial Susceptibility Tests for Bacteria which Grow Aerobically. M7-A. NCCLS, Villanova, PA.
19. Erwin, M. E. & Jones, R. N. (1993). Roxithromycin in vitro susceptibility testing of Haemophilus influenzae by NCCLS method. Journal of Antimicrobial Chemotherapy 32, 652-4.
20. Young, R. A., Gonzalez, J. P. & Sorkin, E. M. (1989). Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 37, 8-41.
21. Hardy, D. J., Hensey, D. M., Beyer, J. M., Votjko, C., McDonald, E. J. & Fernandes, P. B. (1988). Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 32, 1710-9.
22. Jones, R. N. (1993). Disk diffusion susceptibility testing of macrolides: the interpretative criteria. In Macrolides, Chemistry, Pharmacology and Clinical Uses (Bryskier, A. J., Butzler, J. P., Neu, H. C. & Tulkens, P. M., Eds), pp. 209-15. Arnette-Blackwell, Paris.
23. Jones, R. N., Doern, G. V., Gerlach, E. H., Hindler, J. & Erwin, M. E. (1994). Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretative criteria for Haemophilus influenzae tested with the Haemophilus test medium. Diagnostic Microbiology and Infectious Disease 18, 243-9.
24. Cooper, B. C., Mullins, P. R., Jones, M. R. & Lang, S. D. R. (1994). Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infections due to Haemophilus influenzae. A meta-analysis of 12 clinical studies. Drug Investigation 7, 299-314.
25. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1995). Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin and roxithromycin by oxyrase agar dilution and E-test methodologies. Journal of Clinical Microbiology 33, 1366-7.
26. Neu, H. C. (1993). Activity of macrolides against common pathogens in vitro. In Macrolides, Chemistry, Pharmacology and Clinical Uses (Bryskier, A. J., Butzler, J. P., Neu, H. C. & Tulkens, P. M., Eds), pp. 167-82. Arnette-Blackwell, Paris.
27. Kirst, H. A. & Sides, G. D. (1989). New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrobial Agents and Chemotherapy 33, 1413-8.
28. Williams, J. D. & Sefton, A. M. (1993). Comparison of macrolide antibiotics. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 11-26.
29. Bryskier, A. & Labro, M. T. (1994). Macrolides, nouvelles perspectives thérapeutiques. Presse Médicale 23, 1762-6.
30. Bryskier, A. (1992). Newer macrolides and their potential target organisms. Current Opinion in Infectious Diseases 5, 764-72.
31. Barlam, T. & Neu, H. C. (1984). In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy 25, 529-31.
32. Croizé, J., Le Noc, P., Bryskier, A., Duborgel, S. & Robert, J. (1987). Activité in vitro de trois macrolides: érythromycine, josamycine et roxithromycine vis-à-vis de 349 bactéries aérobies et anaérobies. Bordeaux Médicale 20, 150-62.
33. Barry, A. L., Jones, R. N. & Thornsberry, C. (1988). In vitro activities of azithromycin (CP 62993), clarithromycin (A-56268; TE 031), erythromycin, roxithromycin, and clindamycin. Antimicrobial Agents and Chemotherapy 32, 752-4.
34. Le Noc, P., Croizé, J., Bryskier, A., Le Noc, D. & Robert, J. (1989). Activité bactériostatique et bactéricide comparée in vitro de cinq macrolides: roxithromycine, oléandomycine, josamycine et spiramycine sur 284 souches bactériennes d'origine hospitalière. Pathologie Biologie 37, 553-9.
35. Soussy, C. J., Chanal, M., Kitzis, M. D., Duval, J., Cluzel, R. & Acar, J. F. (1988). Activité in vitro de la roxithromycine sur les bactéries hospitalières et courbe de concordance. Pathologie Biologie 36, 420-4.
36. Debbia, E., Varaldo, P. E. & Schito, G. C. (1986). In vitro sensitivity of streptococci and staphylococci from clinical material to a novel macrolide: RU 28965. In Macrolides: a Review with an Outlook on Future Developments (Butzler, J.-P. & Kobayashi, H., Eds), pp. 121-4. Excerpta Medica, Amsterdam.
37. Bauernfeind, A. (1993). In-vitro activity of dirithromycin in comparison with other new and established macrolides. Journal of Antimicrobial Chemotherapy 31, Suppl. C, 39-49.
38. Rolston, K. V. I., Le Blanc, B. & Ho, D. H. (1986). In vitro activity of RU 29865, a new macrolide, compared to that of erythromycin. Journal of Antimicrobial Chemotherapy 17, 161-3.
39. Péchère, J.-C. & Auckenthaler, R. (1987). In-vitro activity of roxithromycin against respiratory and skin pathogens. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 1-5.
40. Sefton, A. M., Maskell, J. P., Yong, F. J., Shu-Jing, C. & Williams, J. D. (1988). Comparative in vitro activity of A-56268. European Journal of Clinical Microbiology and Infectious Diseases 7, 798-802.
41. Neu, H. C., Chin, N. X. & Gu, J. W. (1992). The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476 alone and in combinations. Journal of Antimicrobial Chemotherapy 30, Suppl. A, 83-94.
42. Fleurette, J., Brun, Y., Coulet, M. & Forey, F. (1988). Comparison of the in vitro activity of roxithromycin and five other macrolides on staphylococci. British Journal of Clinical Practice 42, Suppl. 55, 13-4.
43. Rolston, K. V., Gooch, G. & Ho, D. H. (1989). In-vitro activity of clarithromycin (A-56268; TE 031) against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 23, 455-7.
44. Rolston, K. V., Ho, D. H., Le Blanc, B. & Bodey, G. P. (1990). Comparative in vitro activity of the new erythromycin derivative dirithromycin against Gram-positive bacteria isolated from cancer patients. European Journal of Clinical Microbiology and Infectious Diseases 9, 30-3.
45. Guggenbichler, J. P., Georgopoulos, A., Scharrer, P., Kobilansky, C., Mühlbacher, J., Georgopoulos, M. et al. (1993). Antimicrobial activity of josamycin against erythromycin-resistant staphylococci as compared to roxithromycin and clarithromycin. Infection 21, 259-61.
46. Goldstein, E. J. C., Citron, D. M., Vagvolgyi, A. E. & Finegold, S. M. (1986). Susceptibility of bite wound bacteria to seven oral antimicrobial agents, including RU-985, a new erythromycin: considerations in choosing empiric therapy. Antimicrobial Agents and Chemotherapy 29, 556-9.
47. Chin, N. X., Neu, N. M., Labthavikul, P., Saha, G. & Neu, H. C. (1987). Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy 31, 463-6.
48. Kern, W., Linzmeier, K. & Kurrle, E. (1989). Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis. Infection 17, 396-7.
49. Knothe, H. & Hauke, W. (1996). Susceptibility of Streptococcus pneumoniae to roxithromycin. In Proceedings of the Third Symposium of New Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 3.05, p. 29.
50. Shah, P. M., Schäfer, V., Hubener, T., Metz, C. & Stille, W. (1987). Bactericidal activity of ofloxacin versus roxithromycin in the treatment of Streptococcus pneumoniae. Drugs 34, Suppl. 1, 9-13.
51. Romeo, M. A., Lo Bue, A. M., Chisari, G., Gismondi, M. R. & Nicoletti, G. (1986). In vitro comparative study of RU 28965 against organisms from oral and vaginal flora. Giornale di Batteriologia Virologia ed Immunologia 79, 16-24.
52. Loza, E., Morosini, M. I., Negri, M. C., Almaraz, F. & Baquero, F. (1996). Low-level erythromycin resistance in Streptococcus pneumoniae and Streptococcus viridans group blood isolates. In Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract E-44, p. 89. American Society for Microbiology, Washington, DC.
53. Muraoka, H., Ogawa, M., Miyazaki, S., Tsuji, A., Kaneko, Y. & Goto, S. (1988). Bacteriological evaluation of a new macrolide, RU 28965. Chemotherapy (Tokyo) 36, Suppl. 4, 18-34.
54. Tsuboi, Y., Inoue, M. & Mitsuhashi, S. (1988). Bacteriological study on RU 28965, a new oral macrolide. Chemotherapy (Tokyo) 36, Suppl. 4, 1-7.
55. Schülin, T., Wennersten, C. B., Eliopoulos, G. M. & Moellering, R. (1996). In vitro activity of RU 64004 against Gram-positive bacteria. In Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-220, p. 138. American Society for Microbiology, Washington, DC.
56. Spencer, R. C & Wheat, P. F. (1992). In vitro activity of roxithromycin against Moraxella catarrhalis. Diagnostic Microbiology and Infectious Diseases 15, Suppl. 4, S63-5.
57. Drabu, Y. J., Mehtar, S. & Blackmore, P. H. (1987). The in vitro activity of roxithromycin (RU 28965) compared with four oral antibiotics. Drugs under Experimental and Clinical Research 13, 201-23.
58. Liebowitz, L. D., Saunders, J. & Koornhof, H. J. (1991). Comparative in-vitro activity of roxithromycin against 80 Branhamella catarrhalis isolates with reference to beta-lactamase production. In Proceedings of the 17th International Congress on Chemotherapy, Berlin, 1991. Abstract 769, p. 191.
59. Barry, A. L. (1992). In vitro potency of nine orally administered antimicrobial agents against three respiratory tract pathogens. European Journal of Clinical Microbiology and Infectious Diseases 11, 867-69.
60. Chardon, H., Bellon, O., Bourgeois, F. & Lagier, F. (1989). Activité comparée de cinq macrolides sur 190 souches de Branhamella catarrhalis. Pathologie Biologie 37, 382-85.
61. Suermondt, G., Denamur, E., Fleuret, A., Laurans, G. & Orfila, J . (1989). In vitro activity of miocamycin compared with pristinamycin and four macrolides on B. catarrhalis. Pathologie Biologie 37, 386-9.
62. Acar, J.-F. & Goldstein, F. W. (1993). In vitro activity against Gram-positive and Gram-negative bacteria. In The New Macrolides, Azalides and Streptogramins; Pharmacology and Clinical Applications (Neu, H. C., Young, L. S. & Zinner, S. H., Eds), pp. 13-24. Marcel Dekker, New York.
63. Tomé, G., Goldberg, M. & Jogo, M. (1994). Bacteriostatic and bactericidal activity of roxithromycin against H. influenzae isolated from patients suffering respiratory tract infections. In Proceedings of the Second International Symposium on Macrolides, Azalides and Streptogramin, Venice, 1994. Abstract 112, p. 20.
64. Bergeron, M. G., Lavoie, G. Y. & Boucher, F. D. W. (1987). Comparative bactericidal activity of cefixime, carumonam, enoxacin and roxithromycin against resistant Haemophilus influenzae including β-lactam tolerant strains. Journal of Antimicrobial Chemotherapy 20, 663-9.
65. Jorgensen, J. H., Redding, J. S. & Howell, A. W. (1986). In vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) against clinical isolates of Haemophilus influenzae. Antimicrobial Agents and Chemotherapy 29, 921-2.
66. Goldstein, F. W., Emirian, M. F., Coutrot, A. & Acar, J. F. (1990). Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 25-8.
67. Struelens, M. J., Nonhoff, C., Lontie, M., Delannoy, P., Lanis, G., Van Pelt, H. et al. (1991). In vitro activity of commonly used oral antimicrobial agents against community isolates of respiratory pathogens. Acta Clinica Belgica 46, 283-9.
68. Nicoletti, G., Pellegrino, M. B., Blandino, G. & Speciale, A. (1986). In vitro activity of RU 28965, a new macrolide, in comparison with erythromycin and ampicillin against Haemophilus species. In Macrolides: a Review with an Outlook on Future Developments (Butzler, J.-P. & Kobayashi, H., Eds), pp. 118-20. Excerpta Medica, Amsterdam.
69. Lapointe, J. R., Lavallée, C., Meilleur, R. & Bourget, C. (1987). Roxithromycin alone and in combination with suiphamethoxazole against Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 21-9.
70. Kurzynski, T. A., Boehm, D. M., Rott-Petri, J. A., Schell, R. F. & Allison, P. E. (1988). Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project. Antimicrobial Agents and Chemotherapy 32, 137-40.
71. Hoppe, J. E. & Eichhorn, A. (1989). Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis. European Journal of Clinical Microbiology and Infectious Diseases 8, 653-4.
72. Brett, M., Short, P. & Beatson, S. (1986). In vitro activity of roxithromycin and other antibiotics against New Zealand clinical isolates of Bordetella pertussis. In Proceedings of the Third Symposium of New Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 8.05, p. 70.
73. Dubreuil, L., Devos, J., Romond, C. & Bryskier, A. (1986). Activité in vitro de la roxithromycine, nouveau macrolide hemisynthétique, envers les anaérobies stricts. Pathologie Biologie 34, 440-4.
74. Dubreuil, L. (1987). In vitro comparison of roxithromycin and erythromycin against 900 anaerobic bacterial strains. Journal Antimicrobial Chemotherapy 20, Suppl. B, 13-9.
75. Dubreuil, L. (1993). Activity of macrolides against anaerobes in vitro. In Macrolides, Chemistry, Pharmacology and Clinical Uses (Bryskier, A. J., Butzler, J.-P., Neu, H. C. & Tulkens, P. M., Eds), pp. 183-96. Arnette-Blackwell, Paris.
76. Pascual, A., Borobio, V., Garcia-Iglesias, M. C. & Perea, E. J. (1987) Comparative in vitro activity of cefodizime, cefpirome, carumonam and RU 28965 with other antimicrobials against anaerobes. Journal of Antimicrobial Chemotherapy 19, 701-3.
77. Kato, N., Miyauchi, M., Sawamura, H., Watanabe, K. & Ueno, K. (1986) Comparative activity of RU 28965, a new macrolide against anaerobic bacteria. Chemotherapy (Tokyo) 36, Suppl. 4, 65-75.
78. Labro, M. T. (1993) Intraphagocytic penetration of macrolide antibiotics. In Macrolides, Chemistry, Pharmacology and Clinical Uses (Bryskier, A. J., Butzler, J.-P., Neu, H. C. & Tulkens, P. M., Eds), pp. 379-88. Arnette-Blackwell, Paris.
79. Carlier, M. B., Zenebergh, A. & Tulkens, P. M. (1987) Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 47-56.
80. Hand, W. L., King-Thompson, N. & Holman, J. W. (1987). Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrobial Agents and Chemotherapy 31, 1553-7.
81. Labro, M. T., Abdelghaffar, H. & Bryskier, A. (1996). Characteristic of cellular accumulation of RU 004 by human neutrophils. Comparison with azithromycin and roxithromycin. In Proceedings of the 36th Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F-224, p. 139. American Society for Microbiology, Washington, DC.
82. Abdelghaffar, H., Vazifeh, D., Bryskier, A. & Labro, M. T. (1996). Investigation of the mechanism underlying the stimulation of neutrophils (PMN) exocytosis by roxithromycin. In Proceedings of the Third Symposium of New Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 9.02, p. 73.
83. Labro, M. T., Abdelghaffar, H., Vazifeh, D. & Bryskier, A. (1996). Roxithromycin uptake by human neutrophils is mediated by a protein kinase A-dependent mechanism. In Proceedings of the Seventh International Congress of Infectious Diseases, Hong Kong, 1996. Abstract 110-18, p. 278.
84. Chastre, J., Brun, P., Fourtillan, J.-B., Soler, P., Basset, G., Manuel, C. et al. (1986). Uptake of a new macrolide antibiotic (RU 28965 - roxithromycin) by human alveolar macrophages. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1986. Abstract 930, p. 267. American Society for Microbiology, Washington, DC.
85. Ishiguro, M., Koga, H., Kohno, S., Hayashi, T., Yamaguchi, K. & Hirota, M. (1989). Penetration of macrolides into human polymorphonuclear leucocytes. Journal of Antimicrobial Chemotherapy 24, 719-29.
86. 3H-macrolides by human macrophages. Microbios 57, 167-8.
87. Anderson, B., Van Rensburg, C. E. J., Jooné, G. & Lukey, P. T. (1987). An in vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 57-68.
88. Labro, M. T. (1996). Intracellular bioactivity of macrolides. Clinical Microbiology and Infection 1, Suppl. 1, S24-30.
89. Labro, M. T., Amit, N., Babin-Chevaye, C. & Hakim, J. (1986). Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro. Antimicrobial Agents and Chemotherapy 30, 137-42.
90. Hara, K., Suyama, N., Yamaguchi, K., Kohno, S. & Saito, A. (1987). Activity of macrolides against organisms responsible for respiratory infections with emphasis on Mycoplasma and Legionella. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 75-80.
91. Jones, R. N. & Barry, A. L. (1987). The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU 965) against Legionella using broth microdilution method. Journal of Antimicrobial Chemotherapy 19, 841-2.
92. Saito, A., Sawatari, K., Yamaguchi, K., Suzuyama, Y., Shigeno, Y. & Hara, K. (1986). The activity of macrolides on organisms responsible for respiratory tract infections with emphasis on Legionella. In Macrolides: a Review with an Outlook on Future Developments (Butzler, J.-P. & Kobayashi, H., Eds), pp. 54-63. Excerpta Medica, Amsterdam.
93. Dournon, E., Pangon, B., Bizet, C. & Buré, A. (1988). In vitro activity of roxithromycin compared with that of three other macrolides against Legionella. British Journal of Clinical Practice 42, Suppl. 55, 17-8.
94. Felmingham, D., Robbins, M. J., Sanghrajka, M., Leakey, A. & Ridgway, G. L. (1991). The in vitro activity of some 14-, 15-, and 16-membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp., and Ureaplasma urealyticum. Drugs under Experimental and Clinical Research 17, 91-9.
95. Fleurette, J. & Bornstein, N. (1987). Susceptibility of Legionella species to roxithromycin. In Proceedings of the 15th International Congress on Chemotherapy, Istanbul, 1987. Abstract 311, p. 155.
96. Jones, R. N. & Erwin, M. E. (1994). Review of the anti-Legionella activity of roxithromycin and the use of the E-test to determine potency. In Second International Symposium on Macrolides, Azalides and Streptogramins, Venice, 1994. Abstract 135, p. 26.
97. Liebers, D. M., Baltch, A. L., Smith, R. P., Hammer, M. C. & Conroy, J. V. (1989). Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions. Journal of Antimicrobial Chemotherapy 23, 37-41.
98. Orfila, J. (1993). Chlamydial infections. In Macrolides, Chemistry, Pharmacology and Clinical Uses (Bryskier, A. J., Butzler, J. P., Neu, H. C. & Tulkens, P. M., Eds), pp. 241-52. Arnette-Blackwell, Paris.
99. Cevenini, R., Rumpianesi, F., Sambri, V. & La Placa, M. (1986). In vitro activity of RU 28965, a new macrolide against Chlamydia trachomatis and Ureaplasma urealyticum. In Macrolides, a Review with an Outlook on Future Developments (Butzler, J.-P. & Kobayashi, H., Eds), pp. 125-57. Excerpta Medica, Amsterdam.
100. Cevenini, R., Sambri, V. & La Placa, M. (1986). Comparative in vitro activity of RU 28965 against Chlamydia trachomatis. European Journal of Clinical Microbiology 5, 598-600.
101. Cevenini, R., Sambri, V., Moroni, A. & La Placa, M. (1988). Comparative analysis of the effect of roxithromycin on the development of Chlamydia trachomatis in cell cultures. British Journal of Clinical Practice 42, Suppl. 55, 24-5.
102. Kato, N , Watanabe, K., Ueno, K., Takeda, A., Ban, Y. & Kawada, Y. (1988). In vitro activity of RU 28965, a new macrolide against Chlamydia trachomatis and Ureaplasma urealyticum. Chemotherapy (Tokyo) 36, Suppl 4, 76-8.
103. Samra, Z., Rosenberg, S. & Luzon, A. (1996). Antimicrobial activity of roxithromycin, erythromycin, doxycycline, and tetracycline against Chlamydia trachomatis in cell culture. In Proceedings of the Third International Symposium on New Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 2.04, p. 21.
104. Orfila, J. & Haider, F. (1992). In vitro susceptibility of C. pneumoniae strain IOL 207 against clarithromycin compared to different other macrolides. In Proceedings of the First International Symposium on Macrolides, Azalides and Streptogramins, Santa Fé, 1992. Abstract 145, p. 32.
105. Orfila, J. & Haider, F. (1992). In vitro activity of roxithromycin on Chlamydia pneumoniae. In Proceedings of the First International Symposium on Macrolides, Azalides and Streptogramins, Santa Fé, 1992. Abstracts 147 and 149, pp. 32 and 33.
106. Scorneaux, B., Orfila, J. & Tulkens, P. M. (1991). Activities of erythromycin and roxithromycin against Chlamydia spp. in a model of J-774 macrophages in relation to their cellular accumulation. In Proceedings of the 17th International Congress on Chemotherapy, Berlin, 1991. Abstract 783, p. 195.
107. Fenelon, L. E., Mumtaz, G. & Ridgway, G. L. (1990). The in vitro antibiotic susceptibility of Chlamydia pneumoniae. Journal of Antimicrobial Chemotherapy 26, 763-7.
108. Bowie, W. R., Shaw, C. E., Chan, D. W. & Black, W. A. (1987). In vitro activity of Ro 15-8074, Ro-19-5247, A-56268 and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy 31, 470-2.
109. Dutilh, B., de Barbeyrac, B., Lafferière, C. & Bébéar, C. (1986). Activité comparée in vitro d'un nouveau macrolide RU 28965 et de l'érythromycine vis-à-vis de Chlamydia trachomatis. Pathologie Biologie 34, 445-7.
110. Ridgway, G. L. (1986). The in vitro activity of macrolides against Chlamydia trachomatis and the genital mycoplasmas. In Macrolides, a Review with an Outlook on Future Developments (Butzler, J.-P. & Kobayashi, H., Eds), pp. 69-73. Excerpta Medica, Amsterdam.
111. Khurana, C. M. & Deddish, P. A. (1985). In vitro efficacy of RU 965 and erythromycin against clinical isolates of Chlamydia trachomatis. In Proceedings of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, 1985. Abstract 204, p. 127.
112. Stamm, W. E. & Suchland, R. (1986). Antimicrobial activity of U-70138 F (paldimycin), roxithromycin (RU 965), and ofloxacin (ORF 18489) against Chlamydia trachomatis in cell culture. Antimicrobial Agents and Chemotherapy 30, 806-7.
113. Rumpianesi, F., Morandotti, G., Sperning, R., Satta, G. & Cevenini, R. (1993). In vitro activity of azithromycin against Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis in comparison with erythromycin, roxithromycin and minocycline. Journal of Chemotherapy 5, 155-8.
114. Gerlach, E. H., Farkas, M., Johnson, K., Weller, R. & Raymon, J. (1986) Susceptibility of Chlamydia trachomatis to a new macrolide RU 965. In Proceedings of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1986. Abstract 927, p. 266.
115. Orfila, J., Haider, F., Schmitt, J. L., Bissac, E. & Bryskier, A. (1993). Comparative activity of roxithromycin against Chlamydia psittaci in vitro. In Proceedings of the Sixth European Congress on Clinical Microbiology and Infectious Diseases, Seville, 1993. Abstract 304, p. 121.
116. Rastogi, N., Goh, K. S., Ruiz, P. & Casal, M. (1995). In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex. Antimicrobial Agents and Chemotherapy 39, 1162-5.
117. Franzblau, S. G. & Hastings, R. C. (1988). In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrobial Agents and Chemotherapy 32, 1758-62.
118. Franzblau, S. G. (1988). Oxidation of palmitic acid by Mycobacterium leprae in an axenic medium. Journal of Clinical Microbiology 26, 18-21.
119. Gelber, R. H. (1990). Progress in the chemotherapy of leprosy: status, issues and prospects. Progress in Drug Research 34, 421-5.
120. Gévaudan, M. J., Sollet, C., Mallet, M. N., Gulian, G., Tissot-Dupont, H. & de Micco, P. (1990). Etude de l'activité de l'azithromycine et de la roxithromycine seules et en associations vis-à-vis de Mycobacterium avium et de Mycobacterium xenopi. Pathologie Biologie 38, 413-9.
121. Bermudez, L. E., Kolonoski, P. & Young, L. S. (1996). Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infection in beige mice. Antimicrobial Agents and Chemotherapy 40, 1033-5.
122. Bermudez, L. E & Young, L. S. (1988). Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor (TNF) against Mycobacterium avium complex. Antimicrobial Agents and Chemotherapy 32, 1149-53.
123. Casal, M., Rodriguez, F. & Villaba, R. (1990). In vitro susceptibility of Mycobacterium avium complex against rifabutin (LM 427) alone and in combination with amikacin, roxithromycin and ethambutol. Revista Espaniola Quimioterapia 3, 86-9.
124. Casal, M., Rodriguez, F. & Villalba, R. (1987). In vitro susceptibility of Mycobacterium avium to a new macrolide (RU 28965). Chemotherapy 33, 255-8.
125. Maugein, J., Fourche, J., Mormède, M. & Pellegrin, J. L. (1989). Sensibilité in vitro de Mycobacterium avium et Mycobacterium xenopi à l'érythromycine, roxithromycine et doxycycline. Pathologie Biologie 37, 565-7.
126. Rastogi, N., Goh, K. S. & Bryskier, A. (1994). Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex. Antimicrobial Agents and Chemotherapy 38, 1433-8.
127. Rastogi, N., Labrousse, V. & Bryskier, A. (1995). Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages. Antimicrobial Agents and Chemotherapy 39, 976-8.
128. Rastogi, N., Goh, K. S., Bryskier, A. & Devallois, A. (1996). Spectrum of activity of levofloxacin against non-tuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampicin, roxithromycin, amikacin, and clofazimine. Antimicrobial Agents and Chemotherapy 40, 2483-7.
129. Young, L. S., Bermudez, L. E., Wu, M. & Inderlied, C. B. (1995). Potential role of roxithromycin against Mycobacterium avium complex. Infection 23, Suppl. 1, S28-32.
130. Naik, S. & Ruck, R. (1989). In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrobial Agents and Chemotherapy 33, 1614-6.
131. Rastogi, N., Goh, K. S. & Bryskier, A. (1993). In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs. Antimicrobial Agents and Chemotherapy 37, 1560-2.
132. Struillou, L., Cohen, Y., Lounis, N., Bertrand, G., Grosset, J., Vildé, J. et al. (1995). Activities of roxithromycin against Mycobacterium avium infection in human macrophages and C57 BL/6 mice. Antimicrobial Agents and Chemotherapy 39, 878-81.
133. Brown, B. A., Wallace, R. J., Onyi, G. O., De Rosas, V. & Wallace, R. J. (1992). Activities of four macrolides, including clarithromycin against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrobial Agents and Chemotherapy 36, 180-4.
134. Forsgren, A. (1993). Antibiotic susceptibility of Mycobacterium marinum. Scandinavian Journal of Infectious Diseases 25, 779-82.
135. Raoult, D. & Drancourt, M. (1991). Antimicrobial therapy of rickettsial disease. Antimicrobial Agents and Chemotherapy 35, 2457-62.
136. De Mol, P., Butzler, J.-P. & Bryskier, A. (1993). Macrolide antibiotics, rickettsial diseases. In Macrolide, Chemistry, Pharmacology, and Clinical Uses (Bryskier, A. J., Butzler, J.-P., Neu, H. C. &Tulkens, P. M., Eds), pp. 277-83. Arnette-Blackwell, Paris.
137. Ives, T. J., Regnery, R. L., Manzewitsch, P. & Kebede, M. (1995). In vitro evaluation of macrolide antibiotics against Bartonella (Rochalimaea) henselae, B. quintana and B. elizabethae via immunofluorescent antibody. In Proceedings of the 35th Interscience Conference Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract E-46, p. 93. American Society for Microbiology, Washington, DC.
138. Garcia-Rodriguez, J. A., Munoz-Bellido, J. L., Fresnadillo, M. J. & Trujillano, I. (1993). In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrobial Agents and Chemotherapy 37, 911-3.
139. Lang, R., Shasna, B., Ifrach, N., Tinman, S. & Rubinstein, E. (1994). Therapeutic effects of roxithromycin and azithromycin in experimental murine brucellosis. Chemotherapy 40, 252-5.
140. Sanson-Le Pors, M. J., Casin, I. M., Thebault, M. C., Arlet, G. & Perol, Y. (1986). In vitro activity of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic, and five quinolone derivatives against Haemophilus ducreyi. Antimicrobial Agents and Chemotherapy 30, 512-53.
141. Miller, S. D., Dangor, Y., Heyns, A. L. & Aubert, E. (1987). The in vitro activity of roxithromycin, erythromycin and clarithromycin against Southern African strains of Haemophilus ducreyi. In Proceedings of the 16th International Congress Chemotherapy, Jerusalem, 1989, p. 216.
142. Lukehart, S. A. & Baker-Zander, S. A. (1988). Roxithromycin (RU 965): effective therapy for experimental syphilis infection in rabbits. Antimicrobial Agents and Chemotherapy 31, 187-90.
143. King, A. & Phillips, I. (1987). The in vitro activity of roxithromycin, a new macrolide antibiotic, in comparison with that of erythromycin. Drugs under Experimental and Clinical Research 13, 563-6.
144. Casellas, J. M., Goldberg, M., Arduiros, S., Farinati, A., Irbarren, M. & Godin, H. (1987). Comparative MIC and MBC of roxithromycin, A-56286 and erythromycin against 600 clinical isolates. In Proceedings of the 15th International Congress Chemotherapy, Istanbul, 1987. Abstract 421, p. 177.
145. Ridgway, G. L. (1987). A review of the in vitro activity of roxithromycin against genital pathogens. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 7-11.
146. Bébéar, C., Renaudin, H., de Barbeyrac, B., Cantet, P. & Quentin, C. (1986). In vitro sensitivity of Ureaplasma urealyticum to RU 28965 compared to erythromycin and josamycin. In Macrolides, a Review with an Outlook on Future Developments (Butzler, J.-P. & Kobayashi, H., Eds), pp. 91-4. Excerpta Medica, Amsterdam.
147. Palu, G., Valisena, S., Sassela, D., Furneri, P. & Meloni, G. A. (1988). Antimycoplasma activity of roxithromycin. British Journal of Clinical Practice 42, Suppl. 55, 21-3.
148. Bébéar, C., Dupon, M., Renaudin, H. & de Barbeyrac, B. (1993). Potential improvements in therapeutic options for mycoplasmal respiratory infections. Clinical Infectious Diseases 17, Suppl 1., 202-7.
149. Sambri, V., Massaria, F., Cevenini, R. & La Placa, M. (1990). In vitro susceptibility of Borrelia burgdorferi and Borrelia hermsii to ten antimicrobial agents. Journal of Chemotherapy 2, 348-50.
150. Preac-Mursic, V., Wilske, B., Schierz, G., Süss, E. & Gross, B. (1989), Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. European Journal of Clinical Microbiology and Infectious Diseases 8, 651-3.
151. Hansen, K., Hovmark, A., Lebech, A. M., Lebech, K., Olsson, I., Halkier-Sorensen, L. et al. (1992). Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Dermato-venereologica 72, 297-300.
152. Péter, O. & Bretz, A. G. (1994). In vitro susceptibility of Borrelia burgdorferi, Borrelia garanii and Borrelia afzelii to 7 antimicrobial agents. In Proceedings of the VIth International Conference Lyme borreliosis, Bologna, 1994. pp. 167-70.
153. Gasser, R., Reisinger, E. & Klein, W. (1993). Combined therapy with roxithromycin and cotrimoxazole of late Lyme disease. In Proceedings of 18th International Congress Chemotherapy, Stockholm, 1993. Abstract 5013, p. 160.
154. Barbour, A. G., Heiland, R. A. & Howe, T. R. (1985). Heterogeneity of major proteins in Lyme disease Borreliae: a molecular analysis of North American and European isolates. Journal of Infectious Diseases 152, 478-84.
155. Péter, O. & Bretz, A. G. (1992). Polymorphism of outer surface proteins of Borrelia burgdorferi as a tool for classification. Zentralblatt für Bakteriologie 277, 28-33.
156. van Dam, A. P., Kuiper, H., Vos, K., Widjojokusumo, A., de Jongh, B. M., Spanjaard, L. et al. (1993). Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clinical Infectious Diseases 17, 708-17.
157. Bryskier, A., Bretz, A. G. & Péter, O. (1996). Lyme disease -in vitro activity of the combination of roxithromycin and minocycline against three subspecies of Borrelia burgdorferi. In Proceedings of the Third Symposium of New Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 1.07, p. 18.
158. Czinn, S., Carr, H. & Aronoff, S. (1986). Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin (RU 28965) and CP 62993 and rifampicin). Antimicrobial Agents and Chemotherapy 30, 328-9.
159. Glupczinski, Y., Lévy, J., Goossens, H., De Mol, P. & Butzler, J.-P. (1993). Macrolides and Helicobacter pylori. In Macrolides, Chemistry, Pharmacology and Clinical Uses (Bryskier, A. J., Butzler, J. P., Neu, H. C. & Tulkens, P. M., Eds), pp. 271-5. Arnette-Blackwell, Paris.
160. Mégraud, F., Brügmannn, D. & Darmaillac, V. (1996). Roxithromycin - MICs and bactericidal effect on Helicobacter pylori. In Proceedings of the Third Symposium of New Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 5.01, p. 47.
161. Goossens, H., De Mol, P., Coigneau, H., Lévy, J., Grados, O., Ghysels, G. et al. (1985). Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU 28965 (a new macrolide) and other agents against enteropathogens. Antimicrobial Agents and Chemotherapy 27, 388-92.
162. Endtz, H. P., Broeren, M. & Mouton, R. P. (1993). In vitro susceptibility of quinolone-resistant Campylobacter jejuni to new macrolide antibiotic. European Journal of Clinical Microbiology and Infectious Diseases 12, 48-50.
163. Sanchez, R., Fernandez-Baca, V., Diaz, M. D., Munoz, P., Rodriguez-Creixems, M. & Bouza, E. (1994). Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides. Antimicrobial Agents and Chemotherapy 38, 1879-82.
164. Devaster, J. M., Vlaes, L., Dediste, A., Glupczynski, Y. & Butzler, J. P. (1996). In vitro activity of faropenem, ketolide RU 004 and five other antibiotics against Campylobacter spp. In Proceedings of the 36th Interscience Conference Antimicrobial Agents Chemotherapy, New Orleans, LA, 1996. Abstract F-222, p. 138. American Society for Microbiology, Washington, DC.
165. Le Noc, P., Bryskier, A., Croizé, J. & Champevolier, D. (1993). Comparative in vitro activity of 9 macrolides against 50 Vibrio cholerae strains. In Proceedings of the 33rd Interscience Conference Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 231, p. 161. American Society for Microbiology, Washington, DC.
166. Pecquet, S., Chachaty, E., Tancrède, C. & Andremont, A. (1991). Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice. Antimicrobial Agents and Chemotherapy 35, 548-52.
167. Watanabe, K., Sawa, K., Sawamura, H., Yamaoka, K., Aoki, M., Kato, N. et al. (1988). Effect of RU 28965 on intestinal bacterial flora in healthy adults. Chemotherapy (Tokyo) 36, Suppl. 4, 191-201.
168. Kuenzi, B., Segessenmann, C. & Gerber, U. (1987). Post-antibiotic effect of roxithromycin, erythromycin and clindamycin against selected Gram-positive bacteria and Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 20, Suppl. B, 39-46.
169. Castillo, J., Gomez-Lus, M. P., Rubio, M. C. & Gomez-Lus, R. (1991). Post-antibiotic effect of clarithromycin against staphylococci. In Proceedings of the 17th International Congress Chemotherapy, Berlin, 1991. Abstract 2107, p. 526.
170. Hamilton-Miller, J. M. T. & Shah, S. (1993). Post-antibiotic effects of miocamycin, roxithromycin and erythromycin on Gram-positive cocci. International Journal of Antimicrobial Agents 2, 105-9.
171. Odenholt-Tornqvist, L., Lowdin, E. & Cars, O. (1991). Pharmacodynamic effects of subinhibitory concentrations of roxithromycin and vancomycin. In Proceedings of the 31st Interscience Conference Antimicrobial Agents Chemotherapy, Chicago, IL, 1991. Abstract 145, p. 123. American Society for Microbiology, Washington, DC.
172. Moneib, N. A., Shibl, A. M., el-Said, M. A. & el-Masry, E. M. (1993). Macrolides induced suppression of virulence factors produced by Staphylococcus aureus. Journal of Chemotherapy 5, 289-92.
173. Kärber, G. (1931). Beitrag zur Kollektiven Behandlung pharmakoligischer Reihenversuche. Archives of Experimental Pathology and Pharmacology 162, 480-505.
174. Zana, J., Muffat-Joly, M., Thomas, D., Orfila, J., Salat-Baroux, J. & Pocidalo, J. J. (1991). Roxithromycin treatment of mouse chlamydial salpingitis and protective effect on fertility. Antimicrobial Agents and Chemotherapy 35, 430-35.
175. Derouin, F., Nalpas, J. & Chastang, C. (1988). Mesure in vitro de l'effet inhibiteur de macrolides, lincosamides et synergestines sur la croissance de Toxoplasma gondii. Pathologie Biologie 36, 1204-10.
176. Chamberland, S., Kirst, H. A. & Current, W. L. (1991). Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay. Antimicrobial Agents and Chemotherapy 35, 903-9.
177. Hofflin, J. M. & Remington, J. S. (1987). In vivo synergism of roxithromycin (RU 965) and Interferon against Toxoplasma gondii. Antimicrobial Agents and Chemotherapy 31, 346-8.
178. Chan, J. & Luft, B. J. (1986). Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice. Antimicrobial Agents and Chemotherapy 30, 323-24.
179. Chang, H. R. & Péchère, J.-C. (1988). In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP 62993] and A-56268) on Toxoplasma gondii. Antimicrobial Agents and Chemotherapy 32, 524-9.
180. Brun-Pascaud, M., Chau, F., Simonpoli, A. M., Girard, P. M., Derouin, F. & Pocidalo, J. J. (1994). Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis. Journal of Infectious Diseases 170, 653-8.
181. Brun-Pascaud, M., Chau, F., Derouin, F. & Girard, P. M. (1996). Experimental evaluation of roxithromycin combined with dapsone or sulfamethoxasole on pneumocystosis and toxoplasmosis dual infections in rat model. In Proceedings of the Third Symposium of New Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 7.11, p. 64.
182. Wéry, M. & Demedts, P. (1988). A study on in vitro activity of roxithromycin against Entamoeba histolytica and Trichomonas vaginalis. British Journal of Clinical Practice 42, Suppl. 55, 33-4.
183. Bryskier, A. & Labro, M. T. (1993). Antiparasitic activity of macrolide antibiotics. In Macrolides, Chemistry, Pharmacology and Clinical Uses (Bryskier, A. J., Butzler, J. P., Neu, H. C. & Tulkens, P. M., Eds), pp. 307-20. Arnette-Blackwell, Paris.
184. Sprinz, E., Mallman, R., Barcellos, S., Silbert, S. & Schestasky, G. (1996). AIDS-related cryptosporidium diarrhea: a pilot study with roxithromycin. In Proceedings of the Third Symposium of New Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 7.26. p. 68.
185. Uip, D. E., Lima, D. M., Amato, V. S. & Neto, V. A. (1996). The use of roxithromycin in diarrhoea caused by Cryptosporidium spp. associated with AIDS. In Proceedings of the Third Symposium of New Macrolides, Azalides and Streptogramins, Lisbon, 1996. Abstract 7.27, p. 68.
186. Engler, K. H., Warner, M. & George, R. C. (1997). In vitro susceptibility of Corynebacterium diptheriae to a new macrolide, HMR3647. In Programs and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997. Abstract F-24, p. 167. American Society for Microbiology, Washington, DC.
187. Renaudin, H., Tully, J. G. & Bébéar, C. (1992). In vitro susceptibilities of Mycoplasma genitalium to antibiotics. Antimicrobial Agents and Chemotherapy 36, 870-2.